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Abstract: Intravitreal administration of anti-vascular endothelial growth factor (VEGF) antibodies
has become the standard treatment for Age-Related Macular Degeneration; however, the knowledge
of their pharmacokinetics is limited. A comprehensive review of the preclinical and clinical
pharmacokinetic data that were obtained in different studies with intravitreal bevacizumab,
ranibizumab, and aflibercept has been conducted. Moreover, the factors that can influence the
vitreous pharmacokinetics of these drugs, as well as the methods that were used in the studies
for analytical determination, have been exposed. These anti-VEGF drugs present different charge
and molecular weights, which play an important role in vitreous distribution and elimination.
The pharmacokinetic parameters that were collected differ depending on the species that were
involved in the studies and on physiological and pathological conditions, such as vitrectomy and
lensectomy. Knowledge of the intravitreal pharmacokinetics of the anti-VEGF drugs that were used
in clinical practice is of vital importance.
Keywords: vascular endothelial growth factor/antagonists & inhibitors; ranibizumab; aflibercept;
bevacizumab; Age-Related Macular Degeneration; pharmacokinetics; intravitreal
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1. Introduction
Age-Related Macular Degeneration (AMD) is the leading cause of irreversible visual impairment
among individuals over the age of 65 years all around the world (between 30 and 50 million people).
It is expected that its prevalence will double in the next few decades, and it is estimated that 280 million
people will be affected by 2040 [1,2].
The disease almost always begins as a non-neovascular form of AMD and it may progress to
the neovascular form in one or both eyes [3]. A progressive deterioration in the macula characterises
the non-neovascular form, which causes central vision loss. The neovascular form is caused by the
abnormal development of blood vessels under the macula, leading to the leakage of fluid and blood
causing inflammation. The latter form progresses more rapidly, and it can cause severe vision loss
within a few months if left untreated [4].
The cause of the disease is multifactorial (i.e. age, ethnic origin and a combination of genetic
and environmental factors) [5]. Several treatments for neovascular AMD have been widely studied,
such as laser photocoagulation and photodynamic eye therapy with verteporfin, but nowadays the
standard treatment consists of intravitreal injections of inhibitors of vascular endothelial growth factor
(anti-VEGF). The anti-VEGF monoclonal antibodies that were used to treat AMD include the approved
intravitreal administration of pegaptanib, ranibizumab, and aflibercept and the off-label intravitreal
administration of bevacizumab and Ziv-aflibercept [6,7].
Nowadays, in clinical practice, it is very difficult to achieve adequate therapeutic drug levels in
the vitreous humour through topical ocular or systemic administration, which is mainly due to the
existence of physiological barriers. Oral treatments could be an attractive treatment option; however,
they have failed to show benefits in combination with intravitreal anti-VEGF treatments and they are
still being evaluated in monotherapy [8]. Therefore, intravitreal injections are still the most appropriate
method for treating pathologies that affect the posterior segment of the eye [9]. The frequency of
administration of anti-VEGF drugs plays a key role, as their administration is currently not standardised
in clinical practice and therefore different administration schedules coexist. Fixed regimens were
evaluated in pivotal studies [10–12], in which the patients received monthly or bimonthly injections on
a continuous basis over the follow up months [10,11,13]. Fixed monthly injections offer the best visual
outcome, but this regimen is not commonly followed outside clinical trials due to the increased number
of required visits to the ophthalmologist [14]. In addition, the followed regimen can have significant
economic repercussions due to the high cost of these treatments [15]. The two most commonly followed
treatment regimens are the pro re nata (PRN), which consists of treating if reactivation, and the Treat
and Extend (T&E) strategy. The latter consists of a proactive treatment regimen where the key is to
treat the patient before the disease activity appears. It was created to reduce the frequency of injections
and it is the most accepted treatment regimen [16,17]. T&E consists of a loading phase of three monthly
injections, followed by a progressive lengthening of the treatment intervals by one or two weeks as
long as no activity is detected [18]. If disease activity is detected during any visit, treatment intervals
are reduced to the interval used prior to the extension. A recent meta-analysis has shown that the
T&E regime has a mean of 6.9 fewer injections at 24 months when compared to monthly injections
yielding similar visual acuity results. Moreover, when compared to the PRN strategy, T&E has revealed
an improvement of 6.18 more letters than PRN in terms of visual gains, however a mean of 1.44 more
injections was required for the T&E as compared to PRN regimen at 12 months [16].
Normally, the frequency of administration should be based on the half-life of the drug (t1/2) in
order to achieve a sustained therapeutic drug concentration in the vitreous. Direct determination of the
vitreous drug levels requires invasive techniques, and for this reason, these type of studies are limited
to the preclinical field [19,20]. Therefore, most clinical pharmacokinetics studies rely on indirect blood
measurements, which have been mainly restricted to pivotal studies, which have not been studied
in the great majority of post-authorisation trials [21,22]. For these reasons, the information that is
available in this field is very limited.
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The present review collects the most relevant aspects of the intravitreal pharmacokinetics of
anti-VEGF drugs in AMD. For that purpose, an extensive review of the preclinical and clinical
pharmacokinetic studies that have been published in this field was carried out. Moreover, information
regarding the factors involved in the vitreous distribution and clearance, the methods for the
quantification of anti-VEGF antibodies, and the utility of population models have also been compiled.
2. Pharmacokinetics of Anti-VEFG Drugs
In is very difficult to perform intravitreal pharmacokinetic studies on humans, given that
taking vitreous samples is an invasive procedure; therefore, most of the studies have focused on
preclinical research.
2.1. Ranibizumab
Ranibizumab is a fragment of a monoclonal antibody that does not contain the Fc region (heavy
chains) and with affinity for all subtypes of VEGF-A (Table 1). It has been approved for the treatment of
neovascular AMD based on the results of two clinical trials (ANCHOR and MARINE), where 0.5 mg was
administered on a monthly regimen observing improvements in visual acuity with gains of 11.3 letters
in the ANCHOR trial and 7.2 letters in the MARINA trial, as compared to the control groups [10,11].
Table 1. Properties of anti-vascular endothelial growth factor (VEGF) antibodies for Age-Related
Macular Degeneration (AMD). Data from [23–25].
Properties
Pharmaceutics 2019, 11, x 3 of 21 
 
pharmacokinetic studies that have been published in this field was carried out. Moreover, 
information regarding the factors involved in the vitreous distribution and clearance, the methods 
for the quantification of anti-VEGF antibodies, and the utility of population models have also been 
compiled. 
2. Pharmacokinetics of Anti-VEFG Drugs 
In is very difficult to perform intravitreal pharmacokinetic studies on humans, given that taking 
vitreous samples is an invasive procedure; therefore, most of the studies have focused on preclinical 
research.  
2.1. Ranibizumab 
Ranibizumab is a fragment of a monoclonal antibody that does not contain the Fc region (heavy 
chains) and with affinity for all subtypes of VEGF-A (Table 1). It has been approved for the treatment 
of neovascular AMD based on the results of two clinical trials (ANCHOR and MARINE), where 0.5 
mg was administered on a monthly regimen observing improvements in visual acuity with gains of 
11.3 letters in the ANCHOR trial and 7.2 letters in the MARINA trial, as compared to the control 
groups [10,11]. 
Table 1. Properties of anti-vascular endothelial growth factor (VEGF) antibodies for Age-Related 
Macular Degeneration (AMD). Data from [23–25]. 
Properties  
  
Ranibizumab Bevacizumab Aflibercept 
Class Antibody fragment Monoclonal antibody Fusion protein 
MW (KDa) 48 149 115 
Net charge Negative Negative Slightly positive 
Binding target VEGF-A VEGF-A VEGF-A, VEGF-B, PIGF 
KD for VEGF165 (pM) 46 58 0.49 
Mw = molecular weight; KD = equilibrium dissociation constant. 
2.1.1. Animal Studies 
In a pharmacokinetic analysis that was performed by Bakri et al., 0.5 mg of ranibizumab was 
intravitreally injected in the right eye of male Dutch-belted rabbits. While using a non-compartment 
model, they determined that the half-life of ranibizumab was 2.88 days in the vitreous humour and 
2.84 days in the aqueous humour. The mean resident time (MRT) was 4 and 6.8 days in vitreous and 
aqueous humour, respectively, and no serum concentrations were detected [21]. 
Other studies have found vitreous half-lives within the same range. A study using I-124 labelled 
ranibizumab in rabbits and quantified by PET/CT obtained a similar vitreous half-life (2.81 days), but 
a two-compartment model was applied in this case [26]. Another study calculated a vitreous half-life 
of 2.75 days with a one-compartment model [27]. In all the aforementioned studies of the 
pharmacokinetics of ranibizumab in rabbits, the standard dose of ranibizumab (0.5 mg/0.05 mL) was 
injected in just one rabbit eye (unilateral injection). However, the authors of the following study 
decided to perform a bilateral injection, with a different dose to the standard. They injected 0.625 
mg/0.05 mL in both eyes, obtaining a vitreous half-life of 2.9 days with a one-compartment model 
[28], which is comparable to the half-life that was calculated in the other conditions. 
Other studies have tested ranibizumab pharmacokinetics in monkeys as a non-human primate 
model. Christoforidis et al. performed a study with owl monkeys with I-124 radiolabelled 
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2.1.1. Animal Studi s
In a pharmacokinetic nalysis that w s perfor ed by Bakri t al., 0.5 mg of ranibizumab was
intravitreally injected in the right eye of male Dutch-belted rabbits. While using a non-compartment
model, they determined th the h lf-life of ranibizumab was 2.88 da s n the vi ous humour and
2.84 days in the aqueous humour. The mean resident time (MRT) was 4 and 6.8 days in vitreous and
aqueous humour, respectively, and no serum concentrations ere detected [21].
Other studies have found vitreous half-lives within the same range. A study using I-124 labelled
ranibizumab in rabbits and quantified by PET/CT obtained a similar vitreous half-life (2.81 days),
but a two-compartment model was applied in this c se [26]. A other tudy c lculated a v treous
half-life of 2.75 days with a one-compartment model [27]. In all the aforementioned studies of the
pharmacokinetics of ranibizumab in rabbits, the standard dose of ranibizumab (0.5 mg/0.05 mL) was
injected in just one rabbit eye (unilateral injection). However, the authors of the following study decided
to perform a bilateral injection, with a different dose to the standard. They injected 0.625 mg/0.05 mL
in both eyes, obtaining a vitreous half-life of 2.9 days with a one-compartment model [28], which is
comparable to the half-life that was calculated in the other conditions.
Other studies have tested ranibizumab pharmacokinetics in monkeys as a non-human primate
model. Christoforidis et al. performed a study with owl monkeys with I-124 radiolabelled ranibizumab
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in the same way as they performed the study in rabbits [26,29]. They obtained a vitreous half-life of
2.73 days after a single intravitreal injection of 0.5 mg/0.05 mL in one eye. Another study, in this case
with cynomolgus monkeys, was performed with a bilateral single injection of ranibizumab, while
testing two different injection doses: 0.5 mg/0.05 mL and 2 mg/0.05 mL [30]. They obtained vitreous
half-lives with a one-compartment model of 2.63 and 3.95 days, respectively. The comparison between
both groups suggests dose-linear vitreous pharmacokinetics. Aqueous humour, retina, and serum
half-lives were also calculated (with a non-compartmental analysis), obtaining values of 2.54, 2.60,
and 3.59 days for the injected dose of 0.5 mg, and 2.63, 2.28, and 3.47 days for the 2 mg injected
dose, respectively. They also concluded that ranibizumab rapidly distributes to the retina, and it is
removed from the vitreous humour through the anterior chamber (ranibizumab was found in the
aqueous humour) and the posterior route (ranibizumab was found in both retinal layers). Moreover,
they suggested that intraocular metabolism does not play a significant role in the elimination of
ranibizumab from the vitreous chamber [30]. Even though Christoforidis and Gaudreault’s studies
differ in the monkey species used and the uni/bilateral injection at the dose of 0.5 mg, the estimated
vitreous half-lives are comparable (2.73 days vs 2.63 days) [29,30].
2.1.2. Human Studies
A population approach of non-linear pharmacokinetic modelling that is based on serum samples
that were collected from patients with AMD enrolled in five clinical trials, receiving from 0.3 to 2 mg
per eye of single or multiple intravitreal ranibizumab estimated a vitreous half-life of nine days [22].
Ranibizumab reached maximum serum concentration approximately 0.5 days after intravitreal
administration and these concentrations were 90,000 times lower than those that were estimated to
be found in the vitreous humour [22]. The estimated serum half-life was two hours, because it is
not a full-length antibody and it lacks the FcRn (the neonatal Fc receptor for IgG) that protects from
lysosomal degradation, ranibizumab is prone to systemic metabolism [22]. Another study performed
three intravitreal injections of ranibizumab (0.5 mg) in AMD patients at monthly intervals. A serum
half-life of 5.8 days was calculated after measuring serum levels. They also found that ranibizumab did
not demonstrate systemic accumulation between the first and third dose, concluding that ranibizumab
is very quickly cleared from the bloodstream [19,31].
Aqueous humour half-life was calculated in the study performed by Krohne et al. They included
patients that were diagnosed with both clinically significant cataract and macular oedema secondary
to AMD, diabetic maculopathy, or retinal vein occlusion. The patients received a single intravitreal
injection (0.5 mg) within 40 days before surgery, in which the aqueous samples were obtained,
obtaining an aqueous half-life of 7.19 days. Moreover, they performed axial length measurements of
the ocular globe in order to correct ranibizumab concentrations for ocular volume, determining that
volume differences did not significantly alter the aqueous half-life (7.15 days) [32].
There is no data available with regards to the vitreous levels of ranibizumab after intravitreal
injection in humans, and consequently vitreous half-life values are no available. One group applied
a mathematical model that was intended for intravitreal pharmacokinetics in rabbits to estimate the
vitreous half-life of ranibizumab in humans. They calculated a vitreous half-life for ranibizumab of
4.75 days while using an experimentally determined mean half-life of bevacizumab in humans [33].
No significant reductions have been observed in the concentration of systemic VEGF levels
between baseline and after intravitreal injections of ranibizumab [34–38] or drug accumulation
between doses [31].
2.2. Bevacizumab
Bevacizumab is a full monoclonal antibody (with Fc fraction) with an affinity for all subtypes of
VEGF-A and systemic indication in the treatment of different types of cancer (breast, colon . . . ) (Table 1).
There is no current indication for AMD, but its mechanism of action and its administration at the level
of the posterior chamber of the eye at a much lower dose (1.25 mg/0.05 mL) have promoted its off-label
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use [39]. In addition, the possibility of splitting up the vial in the pharmacy departments reduces the
cost of the treatment in comparison with the other two drugs that do have the indication [40].
2.2.1. Animal Studies
Bevacizumab vitreous half-life has been estimated at 4.32 days, following a 1.25 mg/0.05 mL
unilateral intravitreal injection in rabbit eyes (non-compartmental analysis), with concentrations that
remain above 10 µg/mL for 30 days [41]. The estimated half-life was 4.88 days and 6.8 days in the serum
while using the same non-compartment model in the aqueous humour [41]. This data is consistent with
the intravitreal pharmacokinetics that were analysed by molecular imaging with I-125-bevacizumab in
a rabbit model (t1/2 = 4.22 days, two-compartment model) [26]. Bakri et al. found that bevacizumab
concentration was higher in the aqueous humour of the fellow eye (uninjected) than in the vitreous,
concluding that bevacizumab enters the fellow eye from the systemic circulation through the anterior
route, reaching the aqueous humour first before diffusing into the vitreous, rather than entering through
the choroidal blood flow [41]. However, very low concentrations of bevacizumab were found in the
aqueous and vitreous humour of the uninjected eye, so this conclusion must be taken with caution.
Higher vitreous half-life values (5.95 days) were obtained in the study that was performed by
Nomoto et al. in a rabbit model (unilateral injection). They also measured the amount of bevacizumab
in iris/ciliary body and retina/choroids, obtaining half-lives in these tissues of 5.74 and 6.23 days,
respectively. However, the higher half-lives that were obtained can be explained, because they
performed an Enzyme-Linked ImmunoSorbent Assay (ELISA) that detected all bevacizumab, i.e.,
free bevacizumab, VEGF-bevacizumab complex and fragments of bevacizumab molecules, whereas the
majority of the studies only measure free bevacizumab levels, as they have been considered as a good
representation of total drug concentration. Moreover, their first sample taken was seven days after
injection, so early data is missing in this study, which could counterfeit the results [42].
Another study has found even higher half-lives in vitreous, aqueous humour, and serum
(6.61 days, 6.51 days, 5.87 days, non-compartmental analysis) when compared to the other studies of
1.25 mg/0.05 mL bevacizumab unilateral injection in rabbit models [43]. They used New Zealand rabbits
instead of Dutch-belted rabbits, together with a high sensitivity ELISA (detection limit 0.001 ng/mL)
detection kit, which could explain the differences that were found. However, when compared to
Bakri’s work, both of the studies found that the maximum concentration was achieved at one day
post-injection in the vitreous humour and after eight days in serum [41,43]. One great advantage of
this study is that anti-bevacizumab antibodies in serum were also measured, concluding that these
anti-bevacizumab antibodies cannot have an important effect on bevacizumab concentration due to
their low concentration [43].
The intravitreal half-life estimated in owl monkeys of 1.25 mg/0.05 mL I-124-bevacizumab
intravitreal injection was 3.6 days, with detectable concentrations up to 28 days [26].
The pharmacokinetics of bevacizumab in cynomolgus monkeys was also tested by ELISA, but in this
case only aqueous humour and serum samples were collected, obtaining half-lives of 2.8 and 12.3 days,
respectively [44], preventing the comparison of both studies.
No activity was detected in other parts of the rabbit body apart from the ocular globe in the
studies that were performed by Christoforidis et al. with I-125 radiolabelled antibodies bevacizumab,
ranibizumab, and aflibercept [26,45]. However, these results are inconsistent with other studies,
where bevacizumab was detected in the brain, heart, and kidney after a single intravitreal injection [46].
2.2.2. Human Studies
Vitreous half-life was estimated to be 6.7 days following a two-compartment model.
Patients received a single dose of 1.25 mg bevacizumab prior to vitrectomy. A peak concentration
of 165 µg/mL was reached on the second day after the intravitreal injection [47]. Another author
found that the vitreous half-life ranged between 2.5 and 7.3 days, with a mean of 4.9 days, after the
administration of 1.25 mg/0.05 mL while using a one-compartmental model. The vitreous samples were
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taken during pars plana vitrectomy [34]. These results should be taken with caution, as only eleven [47]
and three [34] patients, respectively, were used for the pharmacokinetic analysis. Moreover, the fact
that vitrectomy was performed due to collateral complications, such as submacular haemorrhage and
choroidal neovascularization [47] or cataract extraction [34] must also be taken into account. The latter
study also evaluated the serum half-life of bevacizumab, determining it to be 11.3 days [34].
A serum half-life of 18.7 days [19,31] has been estimated after three-single intravitreal doses
of 1.25 mg of bevacizumab. Moreover, its systemic exposure was found to be greater than that og
ranibizumab or aflibercept, with a serum concentration of 1.58 nM, which is higher than the estimated
inhibitory concentration (IC50) for VEGF factor (IC50 = 0.668 nM) [48]. This data suggests the possibility
of adverse effects that are usually associated with the intravenous doses of these drugs, and that could
appear in patients with AMD, macular oedema, etc. [49–51].
Aqueous half-life was estimated to be 9.82 days in humans by non-compartmental analysis.
Patients received a single intravitreal injection of 1.5 mg bevacizumab and within 53 days after
the injection, an aqueous humour sample was obtained during cataract surgery. The patients were
diagnosed with cataract and recurrent macular oedema secondary to AMD. Bevacizumab concentration
peaked on the first day, with a mean concentration of 33.3 µg/mL [52].
The same dose (1.5 mg) was administered in another study and was compared to a higher
dose of 3 mg. The maximum concentration in the aqueous humour was obtained at one day
post-injection for both doses, with an aqueous half-life of 7.85 and 11.69 days for the 1.5 and 3 mg doses,
respectively, calculated by one-compartmental analysis. Double dosing induced a significant higher
peak concentration at baseline, although the aqueous bevacizumab concentration was not significantly
different after six weeks. Therefore, the administration of a double-dose does not significantly increase
the duration of action. This study presents several limitations, as that the enrolled patients suffered
from different retinal diseases and the injection volume was double for the dose of 3 mg in relation to
1.5 mg, which could affect the pharmacokinetic parameters [53].
Regarding the bevacizumab levels in the aqueous humour of the uninjected eye, the study that
was conducted by Meyer et al. found that the concentration of bevacizumab was below the ELISA
detection limit, so no significant levels are expected to be found in the fellow aqueous chamber [54].
2.3. Aflibercept
Aflibercept has a different mechanism than the other two. It is a recombinant fusion protein
that consists of portions from the extracellular domains of the human VEGF receptors 1 and 2,
which are fused with the Fc portion of the human IgG1. Aflibercept has a great affinity for VEGF A, B,
and placental growth factor (P1GF) (Table 1). The data on the pharmacokinetics of aflibercept is scarce
and mostly refers to animal models in comparison with the other two anti-VEGF drugs.
2.3.1. Animal Studies
Christoforidis et al. also performed studies with I-124 radiolabelled aflibercept, obtaining a vitreous
half-life of 4.58 days after a single intravitreal injection of 2 mg/0.05 mL in Dutch-belted rabbits [45].
Another study found a vitreous half-life of 3.92 days in New Zeeland white rabbits [55]. The differences
could be due to the fact that the aflibercept concentration was quantified by an indirect ELISA and
the dose injected was lower, 1.2 mg/0.03 mL. In this study, the aqueous humour and retina/choroid
half-lives were also calculated, which obtained values of 2 and 2.425 days, respectively [55].
Studies in owl monkeys were also performed with I-124 aflibercept, obtaining a vitreous half-life
value of 2.44 days [29], whereas the vitreous half-life value was 2.2 days in cynomolgus macaques
where aflibercept concentration was measured by ELISA [56].
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2.3.2. Human Studies
Serum half-life of aflibercept has been estimated at 11.4 days after three-monthly intravitreal
injections of aflibercept (2.0 mg) in an AMD population. The authors found that aflibercept seemed to
exhibit systemic drug accumulation between the first and third dose [19,31].
Some of the authors explored the relation between systemic exposure to intravitreal aflibercept
injection and systemic pharmacodynamics (blood pressure). They included patients from four different
clinical trials. Aflibercept plasma concentrations quickly decreased over a week to concentrations below
the LLOQ (15.6µg/L) once peak concentrations has been achieved within 1–3 days post-dose. Intravitreal
administrations were not associated with common adverse effects of intravenous anti-VEGF [57].
The authors of this article suggest, that owing to the intermediate size of aflibercept (between
ranibizumab and bevacizumab), the vitreous half-life of aflibercept could be hypothesised to be nine
days since no intravitreal pharmacokinetic studies have been performed in humans with aflibercept [58].
A study conducted in five patients with AMD found an aqueous half-life of approximately nine days
based on aqueous samples. They also found very low plasma levels, suggesting a lack of substantial
plasma exposure [59].
The same author that calculated a vitreous half-life of ranibizumab in humans with a mathematical
model, determining a vitreous half-life of 7.13 days for aflibercept following the same procedure [33].
A compiled list of the different pharmacokinetic parameters analysed in the studies of ranibizumab
(Table 2), bevacizumab (Table 3), and aflibercept (Table 4) in different species (rabbit, monkey,
and human) has been included at the end of this section. The compiled parameters include half-life
(t1/2), time taken to reach maximum concentration (Tmax), maximum concentration (Cmax), and area
under the concentration-time curve (AUC). Cmax is reached very early on due to the rapid distribution
of the antibodies through the vitreous humour, so most of the studies assume that their first data
point (normally one day post-injection) corresponds to Tmax. Therefore, the utility of defining Tmax is
sometimes controversial. However, Tmax is shown in the pharmacokinetic tables in order to provide
a time reference corresponding to Cmax.
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Table 2. Pharmacokinetic parameters of intravitreal ranibizumab in different species.
Model Injected Dose Determination Sensitivity PKModel
Sample Time Points
Normal Eyes Vitrectomy Aphakia
Observations Ref.








VH 1, 3, 8, 15, 29
days
2.88 days 1 day 162 µg/mL
No detection in
serum







VH 0, 2, 5, 7, 14,
21, 28, 35 days








VH 0, 2, 5, 7, 14,











0.78 ng/mL 1C VH 1, 8 h; 1, 2, 4, 7,
14, 21, 30, 42,
50, 60 days
2.9 days 1 h 1280 µg/mL Bilateral
injection [28]0.78 ng/mL NC AH 3 days 48 h 57.1 µg/mL








VH 1 h or 1, 2, 5,
14, 30 days
2.75 days 1 h 91.61 µg/mL 2.51days
118.01
µg/mL [27]
AH 1 h 20.38 µg/mL 21.7
µg/mL
Serum
Owl monkeys 0.5 mg/0.05
mL
PET (I-124) 2C
VH 0, 1, 2, 4, 8, 14,




1, 2, 4, 8, 12 h;
1, 2, 4, 8, 14, 21,
28, 35 days






1.5 ng/mL 1C VH 6 h, 2, 3, 5, 8,
11 days
2.63 days 6 h 169 µg/mL Bilateral
injection [30]1.5 ng/mL NC AH 2.54 days 6 h 116 µg/mL
15.6 ng/mL NC Serum
2, 6, 12, 24, 36,
48 h; 4–11
days
3.59 days 6 h 150 µg/mL
Cynomolgus
macaques
2 mg/0.05 mL ELISA
1.5 ng/mL 1C VH 6 h, 2, 3, 5, 8,
11 days
3.95 days 1 day 612 µg/mL Bilateral
injection [30]1.5 ng/mL NC AH 2.63 days 1 day 478 µg/mL
15.6 ng/mL NC Serum
2, 6, 12, 24, 36,
48 h; 4–11
days









1, 3 days; 1–8
weeks
[56]
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Table 2. Cont.
Model Injected Dose Determination Sensitivity PKModel
Sample Time Points
Normal Eyes Vitrectomy Aphakia
Observations Ref.
t1/2 Tmax Cmax AUC t1/2 Cmax AUC t1/2
Human 0.5 mg/0.05
mL
ELISA 10–1000 ng/mL 1C
VH












ELISA LLOQ = 15 pg/mL NC
VH 3 h; 1, 3, 7, 28
days [19,31]AH
Serum 5.8 days 0.11 nM 0.46h·nM
CLIA = Chemoluminiscent immunoassay; ELISA = Enzyme-Linked ImmunoSorbent Assay; PET = Positron Emission Tomography; LLOD = Lower Limit of Detection, LLOQ = Lower
Limit of Quantification, 1C = One-compartment model; 2C = Two-compartment model; NC = Non-compartment model; VH = vitreous humour; AH = aqueous humour; t1/2 = half-life;
Tmax = time taken to reach maximum concentration; Cmax = maximum concentration; AUC = area under the curve.
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Normal Eyes Vitrectomy Aphakia
Observations Ref.










VH 1, 3, 8, 15,
29 days
4.32 days 1 day 400 µg/mL
[41]AH 4.88 days 3 days 37.7 µg/mL









1, 2, 4, 12
weeks
5.95 days 7 days 59.7308 µg/mL
[42]AH 7 days 373.6 ng/mL






VH 0, 2, 5, 7,
14, 21, 28,
35 days














































VH 1, 3, 8, 15,
29 days
6.61 days 1 day 406.25 µg/mL
[43]AH 6.51 days 1 day 5.835 µg/mL










VH 1 h; 1, 2, 5,
14, 30 days
7.06 days 1 h 1021.54mg/mL
6.99
days [62]























1, 2, 4, 8,
12 h; 1, 2, 4,
8, 14, 21,
28, 35 days








VH 1, 3, 7 d; 2,
4, 6, 8
weeks
[44]AH 2.8 days 1 day 49.500 µg/mL
Serum 12.3 days 7 days 1.430 µg/mL








Normal Eyes Vitrectomy Aphakia
Observations Ref.












AH 1 day 10.8 µg/mL 1.5days






VH 3 h; 1, 3, 7,
28 days [19,31]AH














4.9 days 0.66day [34]
AH
Serum 11.3 days
Human 1.5 mg ELISA 1C
VH
1–53 days [52]AH 9.82 days 1 day 33.3 µg/mL
Serum
Human 1.5 mg ELISA 1C
VH
1–60 days [53]AH 7.85 days 1 day 14.86 µg/mL
Serum
Human 3 mg ELISA 1C
VH
1–60 days [53]AH 11.69 days 1 day 27.74 µg/mL
Serum
CLIA = Chemoluminiscent immunoassay; ELISA = Enzyme-Linked ImmunoSorbent Assay; PET = Positron Emission Tomography; LLOD = Lower Limit of Detection, LLOQ = Lower
Limit of Quantification, 1C = One-compartment model; 2C = Two-compartment model; NC = Non-compartment model; VH = vitreous humour; AH = aqueous humour; t1/2 = half-life;
Tmax = time taken to reach maximum concentration; Cmax = maximum concentration; AUC = area under the curve.
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Table 4. Pharmacokinetic parameters of intravitreal aflibercept in different species.
Model Injected dose Determination Sensitivity PK Model Sample Time Points
Normal Eyes Vitrectomy Aphakia
Observations Ref.
t1/2 Tmax Cmax AUC t1/2 Cmax AUC t1/2
Dutch-belted
rabbits
2 mg/0.05 mL PET (I-124) 1C
VH 0, 2, 5, 7, 14, 21,
28, 35 days
4.58 days 0 h No detection in
other organs [45]AH
Serum
Owl monkeys 2 mg/0.05 mL PET (I-124) 2C
VH 0, 1, 2, 4, 8, 14,




1, 2, 4, 8, 12 h; 1,









1, 3 days; 1–8
weeks
[56]











Human 2 mg/0.05 mL ELISA
LLOQ = 1000
pg/mL NC
VH 3 h; 1, 3, 7, 28
days [19,31]AH
Serum 11.4 days 0.45nM
4.32
h·nM
Human 2 mg ELISA
VH 4 h; 1, 3, 7, 14, 28
days [59]AH 11 days 4 h 64.4mg/L
Serum 4 h 0 mg/L
CLIA = Chemoluminiscent immunoassay; ELISA = Enzyme-Linked ImmunoSorbent Assay; PET = Positron Emission Tomography; LLOD = Lower Limit of Detection, LLOQ = Lower
Limit of Quantification, 1C = One-compartment model; 2C = Two-compartment model; NC = Non-compartment model; VH = vitreous humour; AH = aqueous humour; t1/2 = half-life;
Tmax = time taken to reach maximum concentration; Cmax = maximum concentration; AUC = area under the curve.
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3. Pharmacokinetic Considerations
Many factors are involved in the pharmacokinetics of anti-VEGF antibodies, from the physiological
conditions of the eye, to the surgical procedures or the analytical methods, which allow for
their determination.
3.1. Eye Physiological Factors
3.1.1. Distribution-Diffusion in the Vitreous Humour
The distribution of drugs in the vitreous humour is conditioned by its intrinsic characteristics,
such as volume and composition, as well as by the properties of the drug (charge, molecular weight,
and protein binding capacity). The vitreous humour occupies around 80% of the internal volume
of the eye, which is around 4 mL in humans, 1.5 mL in rabbits, and 2 mL in monkeys [65]. It is
an avascular structure that is mainly composed of a hydrophilic polymer of hyaluronic acid and
collagen, which contributes to its consistency and attracts water, which is its majority component (98%).
The central part of the vitreous humour has less of these components than the posterior part, which
makes it more fluid-like. In addition, hyaluronic acid has a negative charge, meaning that the restrictive
diffusion of positively charged molecules may occur [66]. Bevacizumab and ranibizumab are both
negatively charged molecules under physiological conditions, therefore their movement should not
be restricted in the vitreous humour [24]. However, aflibercept is considered to have a mild positive
charge, which might affect its pharmacokinetic properties [25].
On other hand, molecular weight affects drug diffusion, which therefore affects the half-life.
The anti-VEGF molecules are rather heavy molecules (149 KDa, 115 KDa, 48 KDa for bevacizumab,
aflibercept, and ranibizumab, respectively), so they are expected to have a low intravitreal clearance
when compared with small molecules that do not have steric hindrance (in general, intravitreal half-life
increases as molecular weight rises above 10,000 Da) [67]. A comparison of the properties of the three
anti-VEGF inhibitors can be found in Table 1 [23–25].
Moreover, the rheological properties of the vitreous humour change with age, in a process called
liquefaction, in which the vitreous humour is turned into a more liquefied state. Liquefaction might
increase drug diffusion, especially in those with high molecular weight [67]. When compared to
plasma, the concentration and number of proteins in the vitreous humour is low (0.5–1.5 mg/mL in
vitreous vs 60–80 mg/mL in plasma) [68]. The main proteins are collagen (a structural protein), albumin,
and immunoglobulins (non-structural proteins) [69]. The binding of drugs to proteins might reduce its
distribution through the vitreous humour, although this factor does not seem to affect the diffusion of
anti-VEGF drugs [70].
3.1.2. Elimination of Drugs from the Vitreous Humour
The elimination of drugs from the vitreous humour can occur via two different routes, either by
metabolism or by disposal into the systemic circulation. In the case of the anti-VEGF drugs, they do
not appear to suffer metabolism nor degradation in the eye [58,70].
After intravitreal injection, the drugs can be removed to the systemic circulation by two routes:
the anterior route or the posterior route. The anterior route consists of drug diffusion through the
vitreous humour until it reaches the aqueous humour and it is then eliminated through its flow. All the
drugs can be eliminated in this way. Various reports have considered that anti-VEGF drugs are mainly
eliminated through the anterior route [21,28,32,52,71].
The posterior route consists of the secretion of the drug by the epithelium of the ciliary body,
iris, or retinal pigment epithelium [70]. Peters and Heidushka tried to demonstrate that bevacizumab
was also eliminated through the posterior route crossing the blood-retinal barrier. They observed that
bevacizumab immunoreactivity after the intravitreal injection extended over time to the inner layers of
the retina. However, they did not attempt to determine whether or not active transport is involved in
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this process [72,73]. The effect of active transport through the retina is not yet clear, so the impact that
this may have on the drug pharmacokinetics is yet to be defined [74].
3.2. Surgical Ocular Procedures (Lensectomy and Vitrectomy)
The distribution and elimination of anti-VEGF drugs from the vitreous are intimately related to
several ophthalmic surgical procedures. Laude et al. suggest that cataract operated patients could have
a faster clearance of vitreous drugs [67]. However, Krohne et al. found that ocular volume and lens
status have no relevant impact on ocular pharmacokinetics and the duration of action of anti-VEGF
drugs after comparing VEGF suppression times in phakic (natural lens) and pseudophakic (replaced
crystalline lens) human eyes [75].
On the other hand, many patients with macular disease who are being treated with anti-VEGF
drugs require surgical intervention for complications, such as bleeding in the vitreous. It is known that
replacing the gel-like vitreous humour with a less viscous saline or aqueous humour facilitates the
transportation of oxygen, as well as the clearance of VEGF inhibitors and cytokines, reducing oedema
and retinal neovascularisation [76,77]. Additionally, the surgical procedure itself and the use of silicone
oil as vitreous replacement can influence drug pharmacokinetics [78].
There are few studies that correlate the effect of vitrectomy with the pharmacokinetics and these
give very different results. A study performed on rabbits with labelled mAbs with I-124 demonstrated
a reduction in the half-life of anti-VEGF drugs after vitrectomy and lensectomy, going from 4.22 to
2.30 and 2.08 days, respectively, for bevacizumab and from 2.81 to 2.13 and 1.79 days, respectively,
for ranibizumab [60]. The same author also quantified the serum concentration of bevacizumab in
rabbits, finding that the serum levels initially increased following the vitrectomy, but determining
that there were not any significant differences later on [61]. On the contrary, other authors did not
find significant differences on the vitreous half-life on injected bevacizumab in non-vitrectomised vs
vitrectomised eyes in rabbit eyes (7.06 days vs 6.99 days) [62], which suggested that VEGF is a complex
molecule that is not restricted to the elimination by diffusion. However, they did find that vitrectomy
affected the PK parameters in the initial distribution phase in a two-phase fitting [62]. Another study
that was published by the same author on ranibizumab also showed no differences between the
vitreous half-life in normal rabbit eyes (2.75 days) and following the vitrectomy (2.51 days) [27]. In this
case, the parameters were established according to one-phase kinetics.
After a vitrectomy, filling the vitreous cavity with a tamponade, such as silicone oil, is a common
procedure. The impact of silicone-oil filled eyes in the pharmacokinetics of injected bevacizumab
was studied, observing longer Tmax, smaller Cmax, and relatively sustained bevacizumab levels in the
ocular tissues in comparison with non-vitrectomised rabbit eyes [79].
Niwa et al. calculated the aqueous half-life of intravitreally injected ranibizumab and aflibercept
in macaque eyes, even though the majority of the studies were performed in rabbit model. They found
that the aqueous half-life was reduced after the vitrectomy (from 2.3 to 1.4 days for ranibizumab and
from 2.2 to 1.5 days for aflibercept) [56]. However, these results must be taken with caution, due to the
fact that the aqueous half-life might be not comparable to the vitreous half-life.
In summary, there is evidence of a decrease in the half-life of intravitreal injected antibodies after
vitrectomy is performed, although it is not quite clear whether or not these differences are relevant
enough to change the injection interval of anti-VEGF antibodies [64,76]. Moreover, this decrease is
higher when the vitrectomy is performed in combination with a lensectomy. However, these results
come from animal studies and their translation to humans is still controversial, which is mainly due to
the anatomic and physiological differences between the species [76].
3.3. Analytical Methods Used in Pharmacokinetic Studies
The assessment of pharmacokinetic parameters for a drug administered by intravitreal route poses
a challenge. It is not easy to obtain periodic samples of vitreous or aqueous fluids due to the invasive
nature of the method. Moreover, when trying to assess drug systemic levels, the exposure may be low,
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or the technique does not offer the sensitivity that is required to enable pharmacokinetic evaluations of
antibodies. Most of the reported assays are based on ELISA (Enzyme-Linked ImmunoSorbent Assay)
assays, which are considered the “gold standard” method used for the measurement of monoclonal
antibodies [22,30,34]. Although there are a large variety of ELISA methods available for anti-VEGF
antibodies determination, most of the work in this field relies on an indirect determination by VEGF,
where factors, such as the type of VEGF, or the binding affinity, might have a big influence. Out of
the three, ranibizumab is the one that requires a higher sensitivity and a more specific detection
method, since the ranibizumab serum levels are often lower than the levels that can be detected by
conventional methods [21,30]. The pharmacokinetic profile of Fab antibodies (such as ranibizumab) is
characterised by a long elimination of the vitreous half-life and a rapid elimination from the systemic
circulation [80]. Molecules containing a Fc region, such as bevacizumab or aflibercept, have greater
systemic half-lives [58], because they are protected from proteolytic catabolism by binding to the
neonatal Fc receptor (FcRn). However, the impact of FcRn receptor on the intravitreal pharmacokinetics
is still unclear [70]. Additionally, high sensitivity ELISA methods require for drug samples to be
diluted within the detection range, which can add some inaccuracy.
Lowe et al. developed a novel electrochemiluminescence assay (ECLA) that allowed for a more
sensitive determination of ranibizumab in serum. This assay was first used to support some clinical
trials, offering 67 times more sensitivity than a conventional ELISA (20 ng/mL) [81] and with a reporting
range of 0.3–24 ng/mL [82]. More recently, the same authors have presented another novel method that
utilises a high-affinity monoclonal anti-ranibizumab-VEGF-complexes antibody (MARA) to measure
ranibizumab in human serum. The assay format uses a semi-homogeneous solution that specifically
binds to the ranibizumab-VEGF complex, but neither one alone. This new ELISA method has a lower
limit of quantification of 15 pg/mL in human serum [83].
There are still a few studies have attempted to improve the detection method, even though most
of the studies quantify the anti-VEGF drugs concentration by immunoassays. Dickmann et al. assessed
the ability of fluorophotometry to measure the intravitreal pharmacokinetics of fluorescently-labelled
ranibizumab in the rabbit and compared the results to those that were obtained using ELISA in previous
publications, obtaining similar results [84].
Christoforidis et al. tried a different approach by labelling bevacizumab, ranibizumab,
and aflibercept with a radionuclide, such as I-124, to evaluate the pharmacokinetics of the intravitreally
injected anti-VEGF drugs by PET/CT [26,45,60]. The great advantage of this method in comparison to
the traditional ones using ELISA is that the vitreous anti-VEGF antibodies levels can be controlled
without needing to sacrifice the animals at determined time intervals or without taking invasive
samples of the vitreous humour.
HPLC (High Performance Liquid Chromatography) is a fast and low-cost quantification method,
however it is not commonly used in antibodies determinations in biological samples. Giannos et al.
tried to correlate ELISA analytical methods to SE-HPLC (size exclusion high performance liquid
chromatography) on in vitro studies, showing a close and significant correlation between them.
Their SE-HLPC method uses a new marketed column designed for antibodies with a lower limit of
detection (LOD) of 2.19 ng/mL and a lower limit of quantification (LLQ) of 8.79 ng/mL for bevacizumab
and ranibizumab. Aflibercept LOD and LLQ were 8.79 and 17.578 ng/mL, respectively [85]. No in vivo
studies were found that used HPLC as an analytical method for anti-VEGF drugs.
4. Outlooks
All of the pharmacokinetic studies centre their reports on the half-lives of the anti-VEGF drugs in
different compartments (vitreous, aqueous humour, or serum) (Figure 1). Their objective is to explain
the route of elimination of the drug from the eye, in the case of animal studies, or to relate the findings
to possible adverse drug effects when entering the systemic circulation.
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Figure 1. Scheme of the pharmacokinetic profiles after anti-VEGF antibodies intravitreal injection.
Only one study has compared the pharmacokinetics of the three anti-VEGF antibodies that were
used in clinical practice [19]. Avery et al. compared the systemic exposure and the suppression of
VEGF in plasma. Ranibizumab showed the least systemic exposure, whereas bevacizumab presented
the highest with a 35-fold increase in AUC as compared to ranibizumab. These differences further
increase after the thir dose. Aflibercept appears to have the greatest suppression of free plasma
VEGF out of the three, with serum concentrations that exceed its IC50 value (0.068 nM) at three hours
post-injection and remain above this for seven days. In contrast, ranibizumab mean trough levels
remained similar to the baseline [19].
However, no st y has extensively examined the ocular pharmacokinetics of anti-VEGF antibodies
in humans and their relation to the frequency of intravitreal doses. The establishment of the actual
dosage regimens is ainly based on the activity of the disease that is assessed by OCT imaging or
visual acuity and not on the pharmacokinetics of the drugs. An in vitro model in aqueous humour
tried to associate the VEGF-A suppression times with the administratio times, which suggested
that in ividual dosing strategies are possible with a range of suppression of 26 to 69 days [86,87].
In humans, only o e study determined levels of unbo d aflibercept in a case series with seven
patients that were treated over a six-month period with aflibercept and unbound VEGF-A in aqueous
humour remained stable after every month and second month of intravitreal injections, supporting
that bimonthly administrations may be enough in those patients that were treated ith aflibercept [88].
Population pharmacokinetic analysis allows for the drug time-course profiles and the response
dynamics over time to be characterised in a more precise manner. It also allows for the identification of
the intrinsic and extrinsic factors that might be related to the observed drug exposure or response [86].
Population analysis, which is also known as non-linear mixed effects modelling, considers the structural
pharmacokinetic or pharmacokinetic/pharmacodynamic models and stochastic models in order to
account for inter-individual and/or inter-occasion variability and residual unexplained error [89–92].
Regulatory authorities have actually acknowledged the relevance of this discipline for drug approval
and its value for an optimal dose selection in the special subgroups of the population [93,94]. However,
these models are not used in the development of new agents for AMD, and only one author has applied
the concepts of non-linear mixed effects modelling for the characterisation of the pharmacokinetic
time-course profile of ranibizumab in this disease [22].
5. Conclusions
At present, the available pharmacokinetic data on anti-VEGF drugs after intravitreal administration
are s ill limited, despite the fact t t these mole ules re the standard treatment for AMD. In r cent
years, many studies have b en carried out in order to determine th main pharmacokinetic parameters
of anti-VEGF antibodies i different animal species an h ma s, although th diff rences in the
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methods of determination, in the samples analysed, in the time points taken, and the compartmental
analysis, etc., make it difficult to attain standardised values for each anti-VEGF antibody. We believe
that this comprehensive review will be of great use to research groups working on the pharmacokinetics
of intravitreally administered VEGF inhibitors, although further studies are necessary in order to
improve the knowledge in this area.
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